Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes

Laszlo Markasz, Henriette Skribek, Michael Uhlin, Rita Otvos, Emilie Flaberg, Staffan Eksborg, E. Oláh, Gyorgy Stuber, Laszlo Szekely

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Tumors are considered to be possible targets of immunotherapy using stimulated and expanded cytotoxic T-lymphocytes (CTL). It is important to consider the drug-induced effects when chemotherapeutic regimens and CTL-mediated immunotherapy is planned to be used in parallel. In this study, we characterized the effect of 29 frequently used chemotherapeutic agents on the cytotoxic activity of autologous and allogeneic CTLs. We found that treatment of CTLs with the following drugs: docetaxel, vincristine, chlorambucil, mitomycin C, oxaliplatin, doxorubicin, and bleomycin effectively inhibited CTL-mediated killing, without affecting their viability. On the other hand, the following drugs enhanced or permitted efficient CTL-mediated killing in vitro at concentrations comparable with the maximally achieved therapeutic concentration in vivo in humans: daunorubicin, prednisolone, vinorelbine, cisplatin, methotrexate, hydroxyurea, cytarabine, cyclophosphamide, topotecan, epirubicin, fluorouracil, carboplatin, asparaginase, 6-mercaptopurine, and bortezomib. Our results could potentially be used in the future to design new CTL-based adjuvant immunotherapy protocols.

Original languageEnglish
Pages (from-to)283-293
Number of pages11
JournalJournal of Immunotherapy
Volume31
Issue number3
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Cytotoxic T-Lymphocytes
Human Activities
Immunotherapy
oxaliplatin
Pharmaceutical Preparations
docetaxel
Topotecan
Chlorambucil
Asparaginase
6-Mercaptopurine
Epirubicin
Daunorubicin
Hydroxyurea
Carboplatin
Cytarabine
Bleomycin
Cytotoxins
Mitomycin
Vincristine
Prednisolone

Keywords

  • Cancer
  • Chemotherapy
  • Cytotoxic T-lymphocyte-mediated killing
  • Immunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Markasz, L., Skribek, H., Uhlin, M., Otvos, R., Flaberg, E., Eksborg, S., ... Szekely, L. (2008). Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. Journal of Immunotherapy, 31(3), 283-293. https://doi.org/10.1097/CJI.0b013e3181628b76

Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. / Markasz, Laszlo; Skribek, Henriette; Uhlin, Michael; Otvos, Rita; Flaberg, Emilie; Eksborg, Staffan; Oláh, E.; Stuber, Gyorgy; Szekely, Laszlo.

In: Journal of Immunotherapy, Vol. 31, No. 3, 04.2008, p. 283-293.

Research output: Contribution to journalArticle

Markasz, L, Skribek, H, Uhlin, M, Otvos, R, Flaberg, E, Eksborg, S, Oláh, E, Stuber, G & Szekely, L 2008, 'Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes', Journal of Immunotherapy, vol. 31, no. 3, pp. 283-293. https://doi.org/10.1097/CJI.0b013e3181628b76
Markasz, Laszlo ; Skribek, Henriette ; Uhlin, Michael ; Otvos, Rita ; Flaberg, Emilie ; Eksborg, Staffan ; Oláh, E. ; Stuber, Gyorgy ; Szekely, Laszlo. / Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. In: Journal of Immunotherapy. 2008 ; Vol. 31, No. 3. pp. 283-293.
@article{dbfcec724ef642259c6762639b056758,
title = "Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes",
abstract = "Tumors are considered to be possible targets of immunotherapy using stimulated and expanded cytotoxic T-lymphocytes (CTL). It is important to consider the drug-induced effects when chemotherapeutic regimens and CTL-mediated immunotherapy is planned to be used in parallel. In this study, we characterized the effect of 29 frequently used chemotherapeutic agents on the cytotoxic activity of autologous and allogeneic CTLs. We found that treatment of CTLs with the following drugs: docetaxel, vincristine, chlorambucil, mitomycin C, oxaliplatin, doxorubicin, and bleomycin effectively inhibited CTL-mediated killing, without affecting their viability. On the other hand, the following drugs enhanced or permitted efficient CTL-mediated killing in vitro at concentrations comparable with the maximally achieved therapeutic concentration in vivo in humans: daunorubicin, prednisolone, vinorelbine, cisplatin, methotrexate, hydroxyurea, cytarabine, cyclophosphamide, topotecan, epirubicin, fluorouracil, carboplatin, asparaginase, 6-mercaptopurine, and bortezomib. Our results could potentially be used in the future to design new CTL-based adjuvant immunotherapy protocols.",
keywords = "Cancer, Chemotherapy, Cytotoxic T-lymphocyte-mediated killing, Immunotherapy",
author = "Laszlo Markasz and Henriette Skribek and Michael Uhlin and Rita Otvos and Emilie Flaberg and Staffan Eksborg and E. Ol{\'a}h and Gyorgy Stuber and Laszlo Szekely",
year = "2008",
month = "4",
doi = "10.1097/CJI.0b013e3181628b76",
language = "English",
volume = "31",
pages = "283--293",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes

AU - Markasz, Laszlo

AU - Skribek, Henriette

AU - Uhlin, Michael

AU - Otvos, Rita

AU - Flaberg, Emilie

AU - Eksborg, Staffan

AU - Oláh, E.

AU - Stuber, Gyorgy

AU - Szekely, Laszlo

PY - 2008/4

Y1 - 2008/4

N2 - Tumors are considered to be possible targets of immunotherapy using stimulated and expanded cytotoxic T-lymphocytes (CTL). It is important to consider the drug-induced effects when chemotherapeutic regimens and CTL-mediated immunotherapy is planned to be used in parallel. In this study, we characterized the effect of 29 frequently used chemotherapeutic agents on the cytotoxic activity of autologous and allogeneic CTLs. We found that treatment of CTLs with the following drugs: docetaxel, vincristine, chlorambucil, mitomycin C, oxaliplatin, doxorubicin, and bleomycin effectively inhibited CTL-mediated killing, without affecting their viability. On the other hand, the following drugs enhanced or permitted efficient CTL-mediated killing in vitro at concentrations comparable with the maximally achieved therapeutic concentration in vivo in humans: daunorubicin, prednisolone, vinorelbine, cisplatin, methotrexate, hydroxyurea, cytarabine, cyclophosphamide, topotecan, epirubicin, fluorouracil, carboplatin, asparaginase, 6-mercaptopurine, and bortezomib. Our results could potentially be used in the future to design new CTL-based adjuvant immunotherapy protocols.

AB - Tumors are considered to be possible targets of immunotherapy using stimulated and expanded cytotoxic T-lymphocytes (CTL). It is important to consider the drug-induced effects when chemotherapeutic regimens and CTL-mediated immunotherapy is planned to be used in parallel. In this study, we characterized the effect of 29 frequently used chemotherapeutic agents on the cytotoxic activity of autologous and allogeneic CTLs. We found that treatment of CTLs with the following drugs: docetaxel, vincristine, chlorambucil, mitomycin C, oxaliplatin, doxorubicin, and bleomycin effectively inhibited CTL-mediated killing, without affecting their viability. On the other hand, the following drugs enhanced or permitted efficient CTL-mediated killing in vitro at concentrations comparable with the maximally achieved therapeutic concentration in vivo in humans: daunorubicin, prednisolone, vinorelbine, cisplatin, methotrexate, hydroxyurea, cytarabine, cyclophosphamide, topotecan, epirubicin, fluorouracil, carboplatin, asparaginase, 6-mercaptopurine, and bortezomib. Our results could potentially be used in the future to design new CTL-based adjuvant immunotherapy protocols.

KW - Cancer

KW - Chemotherapy

KW - Cytotoxic T-lymphocyte-mediated killing

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=41149094150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149094150&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3181628b76

DO - 10.1097/CJI.0b013e3181628b76

M3 - Article

C2 - 18317359

AN - SCOPUS:41149094150

VL - 31

SP - 283

EP - 293

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 3

ER -